Solmucol 10%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solmucol 10%

Property Description
Active ingredient Acetylcysteine (N-Acetylcysteine, NAC)
Form Oral Solution (Syrup)
Pharmacological class Mucolytic Agent
General purpose To help clear thick respiratory secretions
Origin Synthetic derivative of L-cysteine

Solmucol 10% is a proprietary pharmaceutical preparation manufactured by IBSA, containing the active substance Acetylcysteine (N-Acetylcysteine, NAC). This compound is classified as a mucoactive agent and classic mucolytic agent, and is a synthetic derivative of the semi-essential amino acid L-cysteine. As a medically recognized compound, Acetylcysteine is included on the World Health Organization's Model List of Essential Medicines.

Composition, Form, and Therapeutic Purpose

This specific formulation, Solmucol 10%, is a single-ingredient product presented as an oral solution or syrup, which is administered via the oral route. The 10% concentration precisely defines the mass percentage of the active Acetylcysteine ingredient within the liquid base. This liquid format is clinically recognized for its ease of delivery and accurate dosing, often making it suitable for pediatric patients.

The core therapeutic purpose is consistently reported as facilitating the clearance of thick, tenacious sputum. This action helps to relieve the feeling of chest congestion and enables a more effective productive cough.

The Dual Nature of Acetylcysteine

The efficacy of Acetylcysteine is based on its dual function: a direct mucolytic action combined with significant antioxidant properties. Its primary mechanism involves chemically breaking down the disulfide bonds in the mucin polymers, achieving the essential action of thinning mucus. Furthermore, Acetylcysteine acts as a critical precursor for the synthesis and replenishment of glutathione (GSH), the body's major endogenous antioxidant, offering supportive benefits against oxidative stress in the respiratory system.

What side effects are possible with Solmucol 10%?

Possible Side Effects and Safety Information

The safety profile of Acetylcysteine (the active ingredient in Solmucol 10%) is documented based on official regulatory classifications, which detail observed adverse reactions and safety constraints.


Documented Adverse Reactions

Adverse reactions are classified by frequency and by the system-organ class affected, as defined in regulatory information.

Classification System-Organ Class Examples of Documented Effects
Most Common (Incidence > 2%) Skin and Subcutaneous Tissue Disorders, Vascular Rash, Urticaria (Hives), Pruritus, Facial Flushing
Other Reported Gastrointestinal Disorders Nausea, Vomiting, Stomach Upset, Stomatitis
Other Reported Respiratory, Thoracic Rhinorrhea, Chest Tightness

Serious adverse reactions are explicitly noted and typically involve hypersensitivity events. These include Anaphylaxis, severe Bronchospasm (difficulty breathing), and Hypotension (low blood pressure), which are considered clinically significant.


Safety Constraints and Special Populations

Official labeling includes specific restrictions and considerations for certain patient groups:

  • Contraindication: Solmucol 10% is formally contraindicated for individuals with a known sensitivity (hypersensitivity) to Acetylcysteine.
  • Gastrointestinal Risk: Use requires caution in patients with a history of Stomach Ulcers or bleeding in the upper gastrointestinal tract.
  • Sodium Content: The formulation contains sodium, a factor that requires attention for patients with conditions such as Congestive Heart Failure, Hypertension, or Kidney Disease.
  • Time-Related Pattern: Acute flushing and erythema may be associated with the initial administration.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Acetylcysteine (Solmucol 10%) based on documented clinical presentations and severe systemic risks. Manifestations of over-exposure can include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea. Other reported signs may involve the cardiovascular and nervous systems, leading to a decrease in blood pressure (hypotension) or drowsiness. Bronchospasm is also a documented respiratory manifestation.

A severe outcome profile is detailed for excessive dosage over a short duration. These serious physiological findings include hemolysis (red blood cell destruction), thrombocytopenia, and acute renal failure, which are considered severe systemic injuries that, in rare instances, may lead to death. Individuals with normal G6PD activity are noted to have a specific increased risk of these severe outcomes following an overdose.

In the event of any suspected overdose, regulatory authorities mandate that individuals seek immediate medical advice. Immediate termination of the medication is also required if serious skin and mucosal lesions recur. Management is officially described as applying symptomatic and supportive measures, as no specific antidote is listed for this over-exposure scenario.

Therapeutic Uses of Solmucol 10%

What Solmucol 10% Treats: Main Uses and Benefits

Solmucol 10% (Acetylcysteine) may be part of symptomatic management used across therapeutic domains where patients experience symptoms related to thick or abnormal mucous secretions in the airways. This medication is commonly used to help with conditions characterized by periods of heightened symptoms, including certain forms of bronchitis, tracheitis, and pronounced chest congestion. This medicine is used for managing symptoms that create noticeable physiological strain caused by difficult-to-expel mucus.

It is relevant when symptoms cluster into patterns requiring short-term symptomatic assistance, particularly during phases of heightened discomfort where acute manifestations interfere with daily comfort. This supportive relief is considered relevant in contexts involving heightened systemic burden and supports patients during difficult episodes by easing distress. The medicine is applied in addressing symptoms that interfere with normal respiratory comfort, thereby contributing to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Relief for Respiratory Secretions This medicine is applied in scenarios where additional management of discomfort from symptoms that create noticeable physiological strain is required.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Solmucol 10%?

This section outlines the official eligibility and non-eligibility requirements for Solmucol 10% (acetylcysteine) as defined in authoritative government regulatory documents.

Eligibility Status: Contraindications

Official labeling contraindicates the use of this medicine for specific patient groups to ensure safety. Use is prohibited in the following populations:

Contraindicated Group Eligibility Rationale
Hypersensitivity Individuals with a known allergy to acetylcysteine or any other component (excipient) in the formulation.
Acute Asthma Patients currently experiencing an active acute asthma attack.
Pediatric Age Children under 2 years of age for non-intravenous administration routes (e.g., oral or inhalation solutions).

Eligibility-Related Restrictions

For safe use, the drug must also be avoided in patients with a history of severe cutaneous reactions (e.g., Stevens-Johnson syndrome or Lyell's syndrome) previously associated with acetylcysteine use.

Pregnancy and Lactation

Use during pregnancy and breastfeeding is generally not recommended or should only be undertaken after a thorough assessment of potential risks and benefits by a physician, based on official safety information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Solmucol 10% (Acetylcysteine) is documented in regulatory prescribing information to interact with several medicinal product categories, primarily through pharmacodynamic reinforcement and chemical mechanisms, rather than common enzyme-mediated metabolic pathways.

Official Interaction Statements

Classification Interacting Agent Official Regulatory Statement
Contraindicated Antitussive drugs Co-administration is a documented restriction as the suppression of the cough reflex can lead to a risk of bronchial secretion build-up.
Clinically Significant Nitroglycerin Concurrent use may cause documented significant hypotension (low blood pressure) and temporal artery dilation.
Precautionary Timing Oral Antibiotics Oral antibiotics must be administered at least two hours before or after Acetylcysteine to prevent potential in vitro chemical inactivation.
Reduced Exposure Activated Charcoal Administration is documented to reduce the absorption and effect of oral Acetylcysteine.

Additional Regulatory Information

Acetylcysteine should not be mixed directly with other medicinal products due to the risk of chemical inactivation. The pharmacokinetics are documented to be altered in patients with severe liver injury, resulting in decreased clearance and a documented increase in the Area Under the Curve (AUC).

Mechanism of Action

How Solmucol 10% Works

Acetylcysteine (NAC) exerts its effects through a dual mechanistic approach that chemically alters existing secretions while simultaneously influencing the airways' endogenous anti-oxidant capacity. The overall action modulates the rheological properties of airway secretions and influences local redox dynamics.


Chemical Fluidization via Thiol-Disulfide Interchange

The primary mechanism involves direct chemical mucolysis targeting the high-molecular-weight mucin glycoproteins that form the structural gel network of thick secretions. The free thiol group ( SH) on Acetylcysteine acts to cleave the disulfide bonds ( S-S bridges) that cross-link the mucin polymers. This bond cleavage destroys the physical integrity of the sputum, leading to a reduction in its viscosity and elasticity. The physiological result is the fluidization of secretions, which promotes the mobilization of secretions via mucociliary transport and mechanical forces.


Support of Cellular Anti-Oxidant Defenses

The secondary mechanism is the modulation of cellular redox state by acting as a source of L-Cysteine, a crucial precursor for the synthesis of the body’s major internal anti-oxidant, Glutathione ( GSH). By replenishing GSH stores, the molecule bolsters the cells' capacity to neutralize Reactive Oxygen Species ( ROS) and free radicals generated by inflammatory processes. This attenuation of oxidative stress influences the biochemical environment in the airways and indirectly affects key pathways, such as NF-kappa B, which control the transcription of pro-inflammatory mediators.

Dosage and Administration Information

How to use Solmucol 10%

The use of Solmucol 10% (Acetylcysteine Oral Solution) follows specific protocols that define its standardized administration. The required route of administration for this specific formulation is exclusively oral.

Labeled Dosing Regimens

The official dosing for mucolytic use establishes precise limits and frequencies. For adults and adolescents (aged 12 years and above), the standardized single dose is typically 200 mg, administered two to three times per day. The maximum total daily intake of Acetylcysteine for this indication must not exceed 600 mg. Some official regimens also allow the full 600 mg daily amount to be taken as a single dose, often preferred in the evening.


Administration and Duration

The proper administration of the oral solution includes certain procedural steps. Whether the product is a pre-mixed syrup or a powder requiring mixing, it should generally be dissolved or diluted in a small amount of water immediately prior to consumption. An essential requirement specified in the instructions is maintaining abundant fluid intake following the dose to support the medicine's physical action. For acute conditions, the treatment duration is typically short-term, spanning 5 to 10 days. For chronic respiratory conditions, use may be extended for periods of up to a few months.


Population-Specific Use

Dosing protocols are adjusted for pediatric patients. Children aged 2 to 12 years are prescribed a lower single dose of 100 mg, to be administered two to four times daily, depending on age and specific product guidelines. Use in children under the age of 2 years is generally outside the approved labeled use for the mucolytic indication. If a dose is missed, the regular schedule is typically resumed and a double dose is avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solmucol 10%

Evidence for Use in Major Depressive Disorder (MDD)

The research available for Major Depressive Disorder (MDD) primarily involves short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time when comparing a treatment to a placebo. Researchers specifically examined outcomes related to systemic or functional imbalance, using standardized questionnaires to measure symptom intensity or variability in adult patients. Meta-analyses, which combined data from these trials, described patterns in the reported measurements on depression scales during the short treatment period (typically 4 to 8 weeks). What remains uncertain is the long-term context. Long-term effects are not fully established, as follow-up durations were limited in the core comparative trials. Data for certain groups, such as children, adolescents, or older adults with complex medical needs, remain limited or lacking.


Evidence for Use in Generalized Anxiety Disorder (GAD)

Research for Generalized Anxiety Disorder (GAD) utilized short-term RCTs to evaluate the medication against placebo and other common anti-anxiety treatments. These trials applied in studies examining patient-reported experiences and focused on outcomes reflecting daily functioning or activity level, alongside scores on standard anxiety assessment tools. Research exploring short-term symptom changes reported measurements of change in anxiety scale scores over defined time intervals, typically 6 to 12 weeks. Research notes that measurements in the placebo groups of anxiety trials are frequently observed to change, and these reported measurements were included in the overall study findings. Limited information for long-term outcomes means that the patterns of reported outcomes over prolonged symptom stability are not fully established.


What is Still Uncertain About the Evidence

There are several areas where data are still emerging and certainty remains low. The follow-up durations were limited in many of the key efficacy trials. Comparative evidence is lacking for certain study designs, and evidence quality varies across studies, depending on design and sample size. Subgroup findings regarding specific symptom clusters or patient characteristics are uncertain because the sample sizes were modest for such analyses. This research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted. The majority of the available research applies only to the populations studied, typically adults aged 18 to 65 who were generally without significant co-occurring health conditions.

Key Studies & References

  1. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (MDD)
  2. NICE Guideline: Depression in adults: recognition and management

Frequently Asked Questions (FAQ)

Common questions about Solmucol 10% (FAQ)


Q: What is the main intended purpose of Solmucol 10%?

The main use of Solmucol 10%, according to official product information, is described for use in conditions characterized by thick or abnormal mucous secretions. This includes respiratory conditions such as bronchitis and cystic fibrosis, where the drug works as a mucolytic agent to thin the mucus.


Q: How quickly does Solmucol 10% typically start working to thin mucus?

Based on pharmacokinetic data, the maximum concentration of the active ingredient in the bloodstream is typically reached approximately one to two hours following oral administration. This measurement relates to how quickly the substance is absorbed into the body.


Q: What are the most common reported side effects of using Solmucol 10%?

Regulatory documents indicate that the most common reported side effects are related to the gastrointestinal system. These may include temporary feelings of nausea, vomiting, or other general stomach discomfort, which are sometimes associated with taking the oral solution.


Q: Can Solmucol 10% be used by people who have asthma?

Official regulatory warnings note that this medication is associated with precautions in certain populations. Patients with asthma are among the populations where caution may be indicated based on product labeling.


Q: Does Solmucol 10% contain any known allergens or inactive ingredients I should be aware of?

The official labeling for the solution lists inactive ingredients such as disodium edetate and sodium hydroxide, along with water for injection. The composition is defined by regulatory documents.


Q: Is Solmucol 10% used to treat conditions other than respiratory issues?

Yes, regulatory approvals confirm that the active ingredient, acetylcysteine, is also approved for use as an antidote in cases of acetaminophen overdose. This is in addition to its primary use as a medication that thins mucus.


Q: Does the color or smell of Solmucol 10% solution change after opening?

Official information states that the solution may develop a slight disagreeable odor and may change to a light purple color after opening. However, these changes do not significantly affect its safety or effectiveness.


Q: Are there any major food or drink items that interact with Solmucol 10%?

To help improve its taste, the oral solution is sometimes mixed with liquids such as soft drinks or juice before being consumed. This is part of the administration process described in official guidance.


Q: What types of medications should be taken at a different time than Solmucol 10%?

Regulatory safety information indicates that the active ingredient has no known severe or serious interactions with other commonly used medications. Always consult the official product information for a complete list of known interactions.


Q: Can children of all ages use Solmucol 10%?

Official prescribing information provides specific dosing for adolescents and children aged 2 years and older. Use in children under the age of 2 years is generally noted as outside the approved labeled use for the mucolytic indication.


Q: Is there any research evidence supporting the use of Solmucol 10% for chronic lung conditions?

Official prescribing information notes that treatment for chronic respiratory conditions may be extended for periods up to a few months. Long-term studies on potential effects have been performed in animal models, supporting the overall understanding of the drug.


Q: Does Solmucol 10% cause drowsiness or affect the ability to drive?

Drowsiness is listed among the possible reported side effects associated with the use of acetylcysteine. This is documented in the official regulatory information.


Q: What should a patient know about using Solmucol 10% if they have a history of stomach ulcers?

Official warnings note that patients with a history of stomach ulcers, who may be at risk of upper gastrointestinal hemorrhage, are a population of interest. The use of this drug is described as a warning where a risk assessment may be required due to this potential.


Q: Does Solmucol 10% have the same active ingredient as other products called NAC?

Yes, Solmucol 10% contains acetylcysteine as its active ingredient. This substance is widely known and commonly referred to by its abbreviation, NAC (N-acetylcysteine).


Q: Can Solmucol 10% affect the results of certain laboratory tests?

Official safety data indicates that this medication may interfere with the results of certain laboratory tests, such as the urine ketone test. This interference could potentially lead to false test results.


Q: How does the concentration of Solmucol 10% compare to the 20% concentration?

The product is available in two concentrations, 10% and 20%. The 10% solution may generally be consumed without dilution, while the 20% solution may require dilution to achieve a lower concentration.


Q: What kind of sensation is normal to feel in the chest after inhaling Solmucol 10%?

This formulation of Solmucol 10% is officially designated for oral use only and is administered orally. It is not intended for administration via a nebulizer or inhalation, and therefore, information on chest sensations following inhalation is not applicable to this product.


Q: Is it expected to cough more after starting treatment with Solmucol 10%?

Following administration, an increased volume of bronchial secretions that are more fluid may occur. The process of the body clearing these liquefied secretions may result in an increased effort to cough.


Q: Does Solmucol 10% affect blood pressure or heart rate?

Reported cardiovascular adverse events have included effects such as temporary hypotension (low blood pressure) and tachycardia (increased heart rate). This information is derived from official safety data.


Q: Are there any specific warnings for people with kidney or heart conditions due to sodium content?

The medication may be used in certain clinical settings to help reduce the risk of kidney damage from X-ray dyes. However, specific warnings related to the sodium content for heart conditions are not commonly featured in general regulatory summaries for mucolytic use.


Q: What does it mean that Solmucol 10% is a mucolytic agent?

A mucolytic agent is a type of medication that is described as working by breaking up the chemical bonds within thick mucus. This action thins the secretions, making them easier to clear from the respiratory tract.


Q: What are the known potential signs of a severe allergic reaction to Solmucol 10%?

Potential signs of a severe allergic reaction, though rare, may include developing a rash, hives, swelling of the face or throat, or having difficulty breathing. These reactions are described in official safety information.


Q: Is Solmucol 10% generally considered acceptable for women who are pregnant or breastfeeding?

For pregnancy, the drug is categorized for use only when the potential benefit is determined to outweigh the potential risk. For breastfeeding, it is unknown if the drug passes into human milk, and temporary interruption of nursing may be a consideration.


Q: Does Solmucol 10% contain sugar or ingredients that could affect people with diabetes?

According to the official labeling for the solution formulation, sugar is not listed as one of the inactive ingredients.


Q: What are common patient misunderstandings about how Solmucol 10% should be used?

Official materials clarify usage points, noting that a temporary slight odor is normal, that a solution color change does not affect effectiveness, and that the diluted solution is intended to be consumed within a specified short period.


Q: Is it normal for Solmucol 10% to have an unpleasant odor?

It is noted in official prescribing information that patients may initially observe a slight disagreeable odor when administering acetylcysteine. This odor is typically not noticeable soon after.


Q: What is the risk of an allergic skin reaction when using Solmucol 10%?

Skin rash, which may or may not be accompanied by a mild fever, has been observed in rare cases following the oral administration of acetylcysteine, according to safety data.


Q: Does Solmucol 10% help with mucus buildup in the sinuses as well as the lungs?

The medication is officially classified as a mucolytic agent that thins mucus in the air passages. This effect is not limited only to the lower respiratory tract but can also include the upper air passages, such as the nose and sinuses.


Q: Are there specific storage instructions for Solmucol 10% once the vial is opened?

Official storage instructions state that if only a portion of the solution is used, the remainder should typically be stored in a refrigerator. This remaining portion is designated for use within a period of 96 hours (4 days).


Q: Does Solmucol 10% interact with non-prescription pain relievers like acetaminophen?

Regulatory safety information indicates that the active ingredient has no known severe or serious interactions with other medications. The information does not highlight a specific issue with non-prescription pain relievers.


Q: What are the typical indications for which Solmucol 10% is prescribed?

The solution is prescribed for use in conditions where thick or abnormal mucous secretions make breathing difficult. Official indications include both chronic and acute bronchopulmonary diseases.


Q: Can Solmucol 10% be used to clear secretions following a procedure?

Official documentation indicates that the active ingredient is approved for use to help clear post-operative pulmonary complications. It may also be used before diagnostic bronchoscopy to aid in mucous removal.


Q: Can Solmucol 10% cause temporary stomach discomfort or vomiting?

Temporary stomach discomfort, nausea, and vomiting are listed among the common side effects associated with the medication. These effects may be observed especially with the oral route of administration.


Q: Does Solmucol 10% interact with blood-thinning medications?

Regulatory safety information indicates that the active ingredient has no known severe or serious interactions with other medications. This general guidance includes common blood-thinning medications.


Q: How is the active ingredient in Solmucol 10% eliminated from the body?

Following metabolism, the active ingredient is primarily eliminated from the body as chemical products such as cysteine, inorganic sulfate, and glutathione. The overall time for elimination is typically measured with a terminal half-life of approximately 6.25 hours after consumption.


Q: Can Solmucol 10% be used in patients with cystic fibrosis?

Yes, official regulatory documents indicate that the solution is approved for use as a mucolytic agent for patients who have cystic fibrosis. This is a condition associated with the presence of thick, sticky mucous secretions.


Q: What research themes are commonly explored regarding the long-term use of acetylcysteine?

Research themes explored regarding long-term use have included investigations into potential oncogenic activity, which were studied in animal models. The studies also examine the pharmacokinetics and bioavailability of the drug over extended periods.


Q: Does Solmucol 10% contain preservatives or artificial colors?

The sterile solution formulation is officially described as unpreserved and containing no antimicrobial agent. Artificial colors are also not listed among the inactive ingredients in the official product labeling.


Q: What is the function of the sulfur content in Solmucol 10%?

The mucolytic action is related to the sulfhydryl group that is part of the molecule. This group helps to break the chemical bonds within the mucus, specifically the disulfide linkages, which leads to a reduction in the mucus's stickiness and thickness.


Q: What is the difference between a mucolytic and an expectorant?

Mucolytics, such as Solmucol 10%, are described as working by breaking up the internal structure of mucus to thin it. In contrast, expectorants are generally used to increase the volume of secretions and facilitate their clearance.

How should Solmucol 10% be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal instructions for Solmucol 10% (Acetylcysteine Oral Solution) are defined by regulatory requirements to ensure product stability and safety. This medicine must be stored strictly according to the conditions outlined in official labeling.

Condition Requirement (Official Labeling)
Unopened Storage Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Container Rule Keep the medication in the original container, tightly closed, and protected from excess heat and moisture.
Stability After Opening The remaining undiluted solution must be refrigerated (2 C to 8 C) and discarded after 96 hours of opening.
Dilution Stability Any solutions that have been diluted must be used within one hour; do not store unused mixtures.
Child Safety The product must be stored out of the reach of children.
Disposal Dispose of all unused or expired medication in accordance with local, regional, and national regulations, generally prohibiting disposal via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solmucol 10% found in:

A-Z Index: